WINDLASPharmaceuticals
Windlas Biotech Ltd — Cash Flow Statement
₹736.75
-1.94%
Windlas Biotech Ltd Cash Flow Statement (Annual)
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Free Cash Flow | 15.99 Cr | 71.28 Cr | -9.93 Cr | -5.67 Cr | — |
| Repurchase Of Capital Stock | 0.00 | -4.02 Cr | -27.19 Cr | 0.00 | — |
| Repayment Of Debt | 0.00 | -0.11 Cr | -0.34 Cr | -0.39 Cr | — |
| Capital Expenditure | -52.19 Cr | -37.68 Cr | -70.89 Cr | -14.80 Cr | — |
| End Cash Position | 0.42 Cr | 5.29 Cr | 3.69 Cr | 0.57 Cr | — |
| Beginning Cash Position | 5.29 Cr | 3.69 Cr | 0.57 Cr | 15.93 Cr | — |
| Changes In Cash | -4.86 Cr | 1.60 Cr | 3.12 Cr | -15.36 Cr | — |
| Financing Cash Flow | 1.01 Cr | -15.29 Cr | -43.74 Cr | 130.09 Cr | — |
| Net Other Financing Charges | 4.43 Cr | — | — | — | — |
| Interest Paid Cff | -4.38 Cr | -1.11 Cr | -0.79 Cr | -1.42 Cr | — |
| Cash Dividends Paid | -11.49 Cr | -8.30 Cr | -7.63 Cr | — | — |
| Net Common Stock Issuance | 0.00 | -4.02 Cr | -27.19 Cr | 165.00 Cr | — |
| Common Stock Payments | 0.00 | -4.02 Cr | -27.19 Cr | 0.00 | — |
| Net Issuance Payments Of Debt | 27.01 Cr | -0.34 Cr | -5.68 Cr | -25.20 Cr | — |
| Net Short Term Debt Issuance | 27.01 Cr | -0.23 Cr | -5.34 Cr | -24.81 Cr | — |
| Net Long Term Debt Issuance | 0.00 | -0.11 Cr | -0.34 Cr | -0.39 Cr | — |
| Long Term Debt Payments | 0.00 | -0.11 Cr | -0.34 Cr | -0.39 Cr | — |
| Investing Cash Flow | -74.06 Cr | -92.07 Cr | -14.11 Cr | -154.58 Cr | — |
| Interest Received Cfi | 1.63 Cr | 1.74 Cr | 4.55 Cr | 2.56 Cr | — |
| Net Investment Purchase And Sale | -23.69 Cr | -56.17 Cr | 51.32 Cr | -142.45 Cr | — |
| Net PPE Purchase And Sale | -52.00 Cr | -37.64 Cr | -69.98 Cr | -14.69 Cr | — |
| Sale Of PPE | 0.20 Cr | 0.04 Cr | 0.91 Cr | 0.11 Cr | — |
| Purchase Of PPE | -52.19 Cr | -37.68 Cr | -70.89 Cr | -14.80 Cr | — |
| Operating Cash Flow | 68.19 Cr | 108.96 Cr | 60.97 Cr | 9.13 Cr | — |
| Taxes Refund Paid | -20.88 Cr | -18.65 Cr | -9.72 Cr | -8.88 Cr | — |
| Change In Working Capital | -9.09 Cr | 43.95 Cr | 6.32 Cr | -37.57 Cr | — |
| Change In Other Current Liabilities | 12.15 Cr | 5.21 Cr | 6.60 Cr | 1.52 Cr | — |
| Change In Other Current Assets | -7.64 Cr | 1.76 Cr | -0.97 Cr | -13.71 Cr | — |
| Change In Payable | 35.73 Cr | 43.77 Cr | 24.51 Cr | 23.30 Cr | — |
| Change In Inventory | -19.20 Cr | 12.55 Cr | -16.03 Cr | -17.25 Cr | — |
| Change In Receivables | -30.80 Cr | -19.84 Cr | -8.36 Cr | -31.67 Cr | — |
| Other Non Cash Items | 2.95 Cr | -0.86 Cr | -2.65 Cr | -2.56 Cr | — |
| Stock Based Compensation | 2.46 Cr | 2.07 Cr | 1.01 Cr | 1.81 Cr | — |
| Provisionand Write Offof Assets | 0.10 Cr | 2.75 Cr | 2.27 Cr | 0.35 Cr | — |
| Depreciation And Amortization | 27.98 Cr | 13.44 Cr | 12.36 Cr | 12.15 Cr | — |
| Amortization Cash Flow | 1.10 Cr | 0.25 Cr | 0.20 Cr | 0.22 Cr | — |
| Depreciation | 27.98 Cr | 13.44 Cr | 12.17 Cr | 11.93 Cr | — |
| Gain Loss On Investment Securities | -15.08 Cr | -10.82 Cr | -4.78 Cr | -1.72 Cr | — |
| Net Foreign Currency Exchange Gain Loss | -60000.00 | -50000.00 | -0.03 Cr | -60000.00 | — |
| Gain Loss On Sale Of PPE | -90000.00 | -60000.00 | -0.88 Cr | -0.01 Cr | — |
| Net Income From Continuing Operations | 79.76 Cr | 77.09 Cr | 57.04 Cr | 45.56 Cr | — |
| Issuance Of Capital Stock | — | — | 0.00 | 165.00 Cr | 0.00 |
| Common Stock Issuance | — | — | 0.00 | 165.00 Cr | 0.00 |
| Net Business Purchase And Sale | — | — | — | 0.00 | -103.50 Cr |
| Purchase Of Business | — | — | — | 0.00 | -103.50 Cr |
| Gain Loss On Sale Of Business | — | — | — | 0.00 | -5.65 Cr |
| Other Cash Adjustment Outside Changein Cash | — | — | — | — | 5.82 Cr |
| Sale Of Investment | — | — | — | — | 102.22 Cr |
| Purchase Of Investment | — | — | — | — | -14.74 Cr |
| Sale Of Business | — | — | — | — | 0.00 |
All figures in ₹ Crores. Source: NSE/BSE filings via Bull Run.
More on Windlas Biotech Ltd
Data from NSE/BSE public filings. Educational purposes only. Bull Run is not SEBI-registered. Not investment advice.